July 18, 2019 / 11:38 PM / a month ago

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.

U.S. District Judge Stanley Chesler in New Jersey issued a decision upholding a Bausch patent on the formulation of Relistor, which is used to treat opioid-induced constipation.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2GgeeZy

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below